Efficacy of Natalizumab in Intermediate Uveitis Related to Multiple Sclerosis: A Case Report

Roemer, Ségolène; Bissig, A.; Rocca, Alda; Pasquier, Renaud Du; Guex-Crosier, Yan

doi:10.1055/s-0043-124756

Cited by 7 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There has been only one study developed to assess the safety and efficacy of an anti-CAM-based therapy for NIU as summarized in Table 2 . A case report also demonstrated a downregulation of uveitis clinical activity by natalizumab (α4β1-targeted) in treating intermediate uveitis related to multiple sclerosis at one year [ 58 ]. Another case report has illustrated that Vedolizumab (α4β7-targeted) therapy is able to clinically control uveitis associated with inflammatory bowel disease [ 59 ].…”

Section: Resultsmentioning

confidence: 99%

Adhesion Molecule Targeted Therapy for Non-Infectious Uveitis

Chen

Lightman

Eskandarpour

et al. 2022

IJMS

View full text Add to dashboard Cite

Non-infectious uveitis (NIU) is an inflammatory eye disease initiated via CD4+ T-cell activation and transmigration, resulting in focal retinal tissue damage and visual acuity disturbance. Cell adhesion molecules (CAMs) are activated during the inflammatory process to facilitate the leukocyte recruitment cascade. Our review focused on CAM-targeted therapies in experimental autoimmune uveitis (EAU) and NIU. We concluded that CAM-based therapies have demonstrated benefits for controlling EAU severity with decreases in immune cell migration, especially via ICAM-1/LFA-1 and VCAM-1/VLA-4 (integrin) pathways. P-selectin and E-selectin are more involved specifically in uveitis related to vasculitis. These therapies have potential clinical applications for the development of a more personalized and specific treatment. Localized therapies are the future direction to avoid serious systemic side effects.

show abstract

Section: Resultsmentioning

confidence: 99%

Adhesion Molecule Targeted Therapy for Non-Infectious Uveitis

Chen

Lightman

Eskandarpour

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Retrospective studies have reported improvement of MS-associated uveitis following treatment with interferon-beta or glatiramer acetate [95], as well as mycophenolate mofetil [96]. Furthermore, case reports suggested improvement of refractory MS-associated uveitis following treatment with natalizumab [97], alemtuzumab [98], and the interleukin-1-receptor antagonist anakinra [99]. Despite the minor role for B-cells in MS, B-cell depleting anti-CD20 therapies such as rituximab and ocrelizumab have proven highly effective in the treatment of MS [100].…”

Section: Uveitis Associated With Multiple Sclerosismentioning

confidence: 99%

A Comprehensive Update on Retinal Vasculitis: Etiologies, Manifestations and Treatments

Agarwal

Rübsam

Bonsen

et al. 2022

JCM

View full text Add to dashboard Cite

Retinal vasculitis is characterized by inflammatory involvement of retinal arterioles, venules and/or capillaries and can be associated with a myriad of systemic and ophthalmic diseases. In this review, we have comprehensively discussed the etiologies, clinical manifestations, and presentations of retinal vasculitis. We have also included newer advances in imaging in retinal vasculitis such as OCTA and widefield imaging.

show abstract

“…CD4 + Т-лимфоциты синтезируют и секретируют различные цитокины, в частности, IL-2, IL-4, IL-5, IL-6, IL-10, IL-17, IL-22, IL-23 и интерфероны (IFN), высокие концентрации которых в очаге воспаления способствуют активации патологического процесса, а умеренные, напротив, его хронизации [17,36,60,61,64,87]. IL-6 в настоящее время рассматривается как неспецифический маркер интраокулярной воспалительной реакции, поскольку повышение его концентрации в стекловидном теле отмечается при внутриглазном воспалении как инфекционной, так и аутоиммунной этиологии [24,49,58,60,77,82]. IFNγ, в свою очередь, индуцирует активность тканевых макрофагов и обеспечивает хемотаксис мононуклеаров в зону воспаления [14].…”

Section: иммунологические изменения при хроническом периферическом ув...unclassified

Modern etiological and pathogenetic aspects of chronic peripheral uveitis

2022

View full text Add to dashboard Cite

Intermediate uveitis is among most severe forms of endogenous uveitis which is more common in young people, being characterized by minimal clinical manifestations at early stages of the disorder. A significant and, sometimes, irreversible decrease in visual acuity is associated with development of long-term complications of chronic cintermediate uveitis (CIU), i.e., complicating cataracts (in up to 57% of the cases), cystic maular edema developing at a frequency of up to 31%), as well as ophthalmic hypertension and glaucoma (up to 16% of the patients). The incidence rate of CIU is 1.5 per 100,000 per year. The eye, despite its high immune privilege, is susceptible to infectious and inflammatory diseases. Clinical and histopathological data suggest autoimmune origin of CIU associated with possible response to some endogenous antigen of unknown origin. The main effectors of inflammation in peripheral chorioretinal structures are CD4+T lymphocytes, which are found in paravasal infiltrates and vitreoretinal exudates in CIU. An important role in CIU pathogenesis is attributed to IL-6 and IL-8, TNFá, vascular endothelial growth factor (VEGF), and micro-RNAs, which show increased expression in most CIU patients. Impaired state of intestinal bacterial microbiome is a potential trigger of intraocular inflammation. Genetic predisposition for CIU was also revealed, due to polymorphisms of human leukocyte antigens and some other genes. It is necessary to expand and deepen our knowledge on the disease pathogenesis, in order to develop effective pharmacological treatment of CIU. The article is review of literature discussing the modern scientific ideas concerning etiology and mechanisms of the CIU development.

show abstract

Efficacy of Natalizumab in Intermediate Uveitis Related to Multiple Sclerosis: A Case Report

Cited by 7 publications

References 7 publications

Adhesion Molecule Targeted Therapy for Non-Infectious Uveitis

Adhesion Molecule Targeted Therapy for Non-Infectious Uveitis

A Comprehensive Update on Retinal Vasculitis: Etiologies, Manifestations and Treatments

Modern etiological and pathogenetic aspects of chronic peripheral uveitis

Contact Info

Product

Resources

About